Court Scraps Counterclaims Against J&J Unit

Law360, New York (November 13, 2006, 12:00 AM EST) -- A month after upholding the validity and enforceability of a Johnson & Johnson unit’s patent for the antipsychotic drug Risperdal, a New Jersey district court has thrown out a slew of pending noninfringement and unfair competition counterclaims brought by two generics companies.

The U.S. District Court for the District of New Jersey spared Janssen last week from additional challenges by generic Mylan Pharmaceuticals Inc. and Dr. Reddy’s Laboratories Ltd. to its brand-name drug.

Last month, Judge John C. Lifland approved Janssen’s bid for an injunction against...
To view the full article, register now.